Vaccines
Pfizer BioNTech's mRNA COVID-19 vaccine, BNT162b2, has been prospectively evaluated for safety and immunogenicity in a group of 25 Japanese allogeneic HSCT patients, who received the vaccine in comparison with 19 healthy volunteers. The study found that the vaccine was safe and effective in these patients, with 76%
Pharmaceutical industry
Pfizer, the American multinational pharmaceutical corporation, has announced that a COVID-19 vaccine targeting the Omicron variant will be ready by March, as Omicron now accounts for more than 98% of all new COVID-19 cases in the United States. Meanwhile, Moderna, another leading pharmaceutical company, is also developing an Omicron-specific vaccine,
Pharmaceutical industry
The Irish government has confirmed that it is pursuing the purchase of COVID-19 antiviral and monoclonal antibody treatments, following discussions at a cabinet meeting. The treatments in question are manufactured by Pfizer, GlaxoSmithKline (GSK), and Merck (MSD). Ireland has already indicated its intention to participate in a European Union (EU)
Pharmaceutical industry
The "Chronic Kidney Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report projects a significant growth in the Chronic Kidney Disease Market, with an expected Compound Annual Growth Rate (CAGR) of 6.6% during the forecast period. The market is driven by the increasing
Pharmaceutical industry
The Chronic Kidney Disease market is expected to reach $24.8 billion by 2026, growing at a CAGR of 6.6% during the forecast period. The market is driven by the increasing incidence of chronic kidney diseases, technological advancements in diagnostic tests, and the rising need for early detection. The
Vaccines
Researchers conducted a longitudinal observational study involving 184 employees at a German hospital to assess the mid-term follow-up of the immune response induced by two doses of the BioNTech/Pfizer mRNA-based vaccine, BNT162b2. The study aimed to determine the long-term durability of the induced immune response. The results showed a
Vaccines
As the world grapples with the emergence of new COVID-19 variants, a new market study published by Global Industry Analysts Inc. (GIA) sheds light on the global market trajectory and analytics of COVID-19 vaccines. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post-COVID-19 marketplace. The
Pharmaceutical industry
The Food and Drug Administration is poised to approve Pfizer-BioNTech's COVID-19 booster shots for 12-to-15-year-olds, pending a recommendation from unnamed sources familiar with the decision. The booster will be recommended five months after the older children receive their second vaccine, a departure from the six months currently advised
Vaccines
As the Centers for Disease Control and Prevention (CDC) waits for the Food and Drug Administration (FDA) to decide on authorizing Pfizer and BioNTech's COVID-19 booster shot for younger teens, vaccine stocks experienced a downturn, with BioNTech stock falling 0.3% and Pfizer stock slipping 0.7%. The
Pharmaceutical industry
The global antifungal drugs market has exhibited moderate growth from 2015-2020, driven by increasing prevalence of fungal and nosocomial infections. According to a report, the market is expected to grow at a compound annual growth rate (CAGR) of around 4% from 2021-2026. The market is driven by the convenient availability
Vaccines
Makati City Mayor Abby Binay has called on residents to get themselves boosted against COVID-19, citing the threat of the virus's Delta and Omicron variants. The city's local government unit (LGU) has ramped up its information campaign and vaccination programs in response to the Department of
Pharmaceutical industry
The US FDA has authorized the first pill against COVID-19, a Pfizer drug called Paxlovid, which can be taken at home to prevent severe symptoms. The move comes as cases, hospitalizations, and deaths are rising, with health officials warning of a potential tsunami of new infections from the Omicron variant.
